Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPIK-L1: Alpelisib in PIK3CA-Mutated Lymphatic Malformations
NCT05948943Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Nov 2023
- Primary completion
- May 2028
- Countries
- 12
01
Overview
A Phase 3 trial of alpelisib in Lymphatic Malformation (LM), sponsored by Novartis. Started Nov 2023; status: recruiting.
02
Drugs
alpelisib
03
Conditions
Lymphatic Malformation (LM)
Beyond the preview
Go deeper on NCT05948943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05948943.